Biologic Therapy in Moderate-to-Severe Ulcerative Colitis: Infliximab

  • Mindy Lam
  • Brian BresslerEmail author


The role of tumor necrosis factor α (TNF-α) proinflammatory cytokine in the pathogenesis of ulcerative colitis (UC) has been debated [1–5]. Inflammatory cascade involves activation of CD4+ T-lymphocytes into T helper (Th)-1 and Th-2 cells. Activation of Th-1 cells leads to secretion of interferon gamma (IFNγ), and interleukin (IL)-2, IL-12, and IL-18. In contrast, activation of Th-2 cells leads to secretion of IL-4, IL-5, IL-6, IL-10, and IL-13. TNF-α expression from macrophages and monocytes is stimulated by Th-1 response by the release of IFNγ.


Ulcerative Colitis Infliximab Therapy Infliximab Group Clinical Remission Rate Infliximab Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Mizoguchi E, Mizoguchi A, Takedatsu H, Cario E, de Jong YP, Ooi CJ, et al. Role of tumor necrosis factor receptor 2 (TNFR2) in colonic epithelial hyperplasia and chronic intestinal inflammation in mice. Gastroenterology. 2002;122(1):134–44.CrossRefPubMedGoogle Scholar
  2. 2.
    Melgar S, Yeung MM, Bas A, Forsberg G, Suhr O, Oberg A, et al. Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis. Clin Exp Immunol. 2003;134(1):127–37.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Leeb SN, Vogl D, Gunckel M, Kiessling S, Falk W, Goke M, et al. Reduced migration of fibroblasts in inflammatory bowel disease: role of inflammatory mediators and focal adhesion kinase. Gastroenterology. 2003;125(5):1341–54.CrossRefPubMedGoogle Scholar
  4. 4.
    Ten Hove T, The Olle F, Berkhout M, Bruggeman JP, Vyth-Dreese FA, Slors JF, et al. Expression of CD45RB functionally distinguishes intestinal T lymphocytes in inflammatory bowel disease. J Leukoc Biol. 2004;75(6):1010–5.CrossRefPubMedGoogle Scholar
  5. 5.
    Amasheh S, Barmeyer C, Koch CS, Tavalali S, Mankertz J, Epple HJ, et al. Cytokine-dependent transcriptional down-regulation of epithelial sodium channel in ulcerative colitis. Gastroenterology. 2004;126(7):1711–20.CrossRefPubMedGoogle Scholar
  6. 6.
    Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest. 2004;113(10):1490–7.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Sawa Y, Oshitani N, Adachi K, Higuchi K, Matsumoto T, Arakawa T. Comprehensive analysis of intestinal cytokine messenger RNA profile by real-time quantitative polymerase chain reaction in patients with inflammatory bowel disease. Int J Mol Med. 2003;11(2):175–9.PubMedGoogle Scholar
  8. 8.
    Sands BE, Kaplan GG. The role of TNFa in ulcerative colitis. J Clin Pharmacol. 2007;47(8):930–41.CrossRefPubMedGoogle Scholar
  9. 9.
    Theiss AL, Simmons JG, Jobin C, Lund PK. Tumor necrosis factor (TNF)a increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J Biol Chem. 2005;280:36099–109.CrossRefPubMedGoogle Scholar
  10. 10.
    Remicade. Janssen. 2015.Google Scholar
  11. 11.
    Langholz E, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology. 1992;103:1444–51.CrossRefPubMedGoogle Scholar
  12. 12.
    Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001;7(2):83–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Probert CS, Hearing SD, Schreiber S, Kuhbacher T, Ghosh S, Amott ID, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52(7):998–1002.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Ochsenkuhn T, Sackmann M, Goke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol. 2004;16(11):1167–71.CrossRefPubMedGoogle Scholar
  15. 15.
    Jamerot G, Hertervig E, Frils-Liby K, Blomquist L, Karlen P, Granno C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128(7):1805–11.CrossRefGoogle Scholar
  16. 16.
    Chey WY. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis. 2001;7 Suppl 1:S30–3.CrossRefPubMedGoogle Scholar
  17. 17.
    Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–76.CrossRefPubMedGoogle Scholar
  18. 18.
    Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137(4):1250–60.CrossRefPubMedGoogle Scholar
  20. 20.
    Panaccione R, Ghosh S, Middleton S, Marquez JR, Scott BB, Flint L, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392–400.CrossRefPubMedGoogle Scholar
  21. 21.
    Bressler B, Marshall JK, Bernstein CN, Bitton A, Johnes J, Leontiadis GI, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148(5):1035–58.CrossRefPubMedGoogle Scholar
  22. 22.
    Armuzzi A, Pugliese D, Danese S, Rizzo G, Felice C, Marzo M, et al. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopoic remission. Inflamm Bowel Dis. 2013;19(5):1065–72.CrossRefPubMedGoogle Scholar
  23. 23.
    Christophorou D, Funakoshi N, Duny Y, Valats JC, Bismuth M, Pineton De Chambrun G, et al. Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis. Aliment Pharmacol Ther. 2015;41(7):603–12.CrossRefPubMedGoogle Scholar
  24. 24.
    Baron TH, Truss CD, Elson CO. Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sci. 1993;38(10):1851–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Cummings JR, Herrlinger KR, Travis SP, Gorard DA, McIntyre AS, Jewell DP. Oral methotrexate in ulcerative colitis. Aliment Pharmacol Ther. 2005;21(4):385–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Khan N, Abbas AM, Moehlen M, Balart L. Methotrexate in ulcerative colitis: a nationwide retrospective cohort from the Veterans Affairs Health Care System. Inflamm Bowel Dis. 2013;19(7):1379–83.CrossRefPubMedGoogle Scholar
  27. 27.
    Chande N, Wang Y, MacDonald JK, McDonald JW. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2014;8:CD006618.Google Scholar
  28. 28.
    Feagan BG, McDonald JW, Panaccione R, Enns RA, Bernstein CN, Ponich TP, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology. 2014;146(3):681–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Bitton A, Buie D, Enns R, Feagan BG, Jones JL, Marshall JK, et al. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol. 2012;107(2):179–94.CrossRefPubMedGoogle Scholar
  30. 30.
    Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;19(3):CD005112.Google Scholar
  31. 31.
    Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59(1):49–54.CrossRefPubMedGoogle Scholar
  32. 32.
    Adedokun OJ, Sandborn WJ, Feagan BG, Rutgeerts P, Xu Z, Marano CW, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014;147(6):1296–307.CrossRefPubMedGoogle Scholar
  33. 33.
    Safety update on TNF-a antagonists: infliximab and etanercept. 2015. Accessed Aug 2015.
  34. 34.
    Cheent K, Nolan J, Shariq S, Kiho L, Pal A, Arnold J. Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn’s disease. J Crohns Colitis. 2010;4(5):603–5.CrossRefPubMedGoogle Scholar
  35. 35.
    Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Langholff W, et al. Drug therapies and the risk of malignancy in Crohn’s disease: results from the TREAT™ Registry. Am J Gastroenterol. 2014;109(2):212–23.CrossRefPubMedGoogle Scholar
  36. 36.
    Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6(6):644–53.CrossRefPubMedGoogle Scholar
  37. 37.
    Moulis G, Sommet A, Lapeyre-Mestre M, Montastruc JL. Association Francaise des Centres Regionaux de PharmacoVigilance. Rheumatology (Oxford). 2014;54(10):1864–71.CrossRefGoogle Scholar
  38. 38.
    Famenini S, Wu JJ. Infliximab-induced psoriasis in treatment of Crohn’s disease-associated ankylosing spondylitis: case report and review of 142 cases. J Drugs Dematol. 2013;12(8):939–43.Google Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Division of GastroenterologyUniversity of British ColumbiaVancouverCanada

Personalised recommendations